Among these HATis, A485 and CCS-1477 hold the greatest promise for future preclinical studies, owing to their high specificity against p300/CBP, potent and orally bioavailable formulation, relatively robust efficacy at HAT inhibition, and specific toxicity in only MCPyV+ MCC (Figs S2 and 9) [53,56,88]. This evidence concerns the gene EP300 and Merkel cell skin cancer.